Article Sidebar
Published:
Jul 19, 2021Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Effect of Acorus tatarinowii extract on hyperprolactinemia in rats
Abstract
Purpose: To determine the mechanism underlying the anti-hyperprolactinemia effect of Acorus tatarinowii extract (ATE) in rats.
Methods: Rats were divided into six groups (n =10 each group), viz, healthy control, untreated hyperprolactinemic rats, hyperprolactinemic rats treated with bromocriptine (0.6 mg/kg), and hyperprolactinemic rats treated with ATE (3.2, 6.4, or 12.8 g/kg). After 30 days, the hypothalamic protein levels of dopamine D2 receptor, protein kinase A (PKA), and cyclic adenosine monophosphate (cAMP) were determined.
Results: Dopamine D2 receptor levels were lower in untreated hyperprolactinemic rats than in healthy control (p < 0.01), but this decrease was attenuated by ATE (p < 0.05). Elevated PKA levels in untreated hyperprolactinemic rats (0.78 ± 0.03µg/mL, p < 0.01) were decreased by ATE (3.2 g/kg, 0.51 ± 0.02 µg/mL, p < 0.05; 6.4 g/kg, 0.39 ± 0.03 µg/mL, p < 0.01; 12.8 g/kg, 0.24 ± 0.04 µg/mL, p < 0.01). Similarly, elevated cAMP levels in hyperprolactinemic rats (3.1 ± 0.3 ng/mL) were lowered by ATE (3.2 g/kg, 2.2 ± 0.4 ng/mL, p < 0.05; 6.4 g/kg, 1.8 ± 0.3 ng/mL, p < 0.01; 12.8 g/kg, 1.4 ± 0.3 ng/mL, p < 0.01).
Conclusion: ATE anti-hyperprolactinemia activity is mediated by dopamine D2 receptor signaling via cAMP/PKA pathway.
